CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $9.01M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -0.49: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
360.30MUSDvs all stocks (USD)
Revenue (TTM)
9.01MUSDvs all stocks (USD)
Beta
0.3540xvs all stocks
52-Week Change
149.68%vs all stocks
Market Capitalization
360.30MUSDvs all stocks (USD)
Enterprise Value
203.83MUSDvs all stocks (USD)
Forward P/E
-4.66xvs Biotechnology peers
Price to Sales (TTM)
39.97xvs Biotechnology peers
Price to Book (MRQ)
2.14xvs Biotechnology peers
Enterprise to Revenue
22.61xvs Biotechnology peers
Enterprise to EBITDA
-2.27xvs Biotechnology peers
Gross Margin
77.92%vs Biotechnology peers
Operating Margin
-748.49%vs Biotechnology peers
Return on Assets (TTM)
-28.33%vs Biotechnology peers
Return on Equity (TTM)
-104.21%vs Biotechnology peers
Revenue (TTM)
9.01MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1250USDUpdated Jul 19, 2026Quarterly Revenue Growth
-90.60%vs Biotechnology peers
Gross Profit (TTM)
7.38MUSDvs all stocks (USD)
EBITDA (TTM)
-89.69MUSDvs all stocks (USD)
Net Income (TTM)
-99.72MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-92.85MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-55.17MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
35.11MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
5.76MUSDFY2025 · Dec 31, 2025Gross Profit
29.36MUSDFY2025 · Dec 31, 2025Operating Income
-86.88MUSDvs all stocks (USD)
Pre-tax Income
-79.16MUSDFY2025 · Dec 31, 2025Income Tax Expense
41.00KUSDFY2025 · Dec 31, 2025Net Income
-79.20MUSDFY2025 · Dec 31, 2025EBIT
-70.28MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-81.78MUSDFY2025 · Dec 31, 2025Research & Development
72.72MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
43.52MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.58MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
8.88MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-79.20MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-75.06MUSDFY2025 · Dec 31, 2025Free Cash Flow
-75.06MUSDDerived from operating cash flow minus capital expenditure. This filing charges 1.28M of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads -88.62M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
217.85MUSDFY2025 · Dec 31, 2025Interest Paid
8.05MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-79.20MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.28MUSDFY2025 · Dec 31, 2025Stock-based Compensation
4.30MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.36MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
497.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.98MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.32MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Net Intangibles (CF)
-3.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-63.39MUSDFY2025 · Dec 31, 2025Sale of Investments
74.54MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
11.15MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
238.53MUSDFY2025 · Dec 31, 2025Shares Outstanding
94.32MSharesUpdated Jul 19, 2026Float Shares
57.53MSharesUpdated Jul 19, 2026Shares Short
5.51MSharesUpdated Jul 19, 2026Short Ratio
5.54daysvs all stocks
Short % of Shares Outstanding
5.85%vs all stocks
% Held by Insiders
0.54%vs all stocks
% Held by Institutions
99.77%vs all stocks
Total Cash (MRQ)
233.72MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.48USDUpdated Jul 19, 2026Total Debt (MRQ)
77.25MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.4586xvs Biotechnology peers
Current Ratio (MRQ)
10.18xvs Biotechnology peers
Book Value per Share (MRQ)
1.79USDUpdated Jul 19, 2026Total Assets
290.46MUSDvs all stocks (USD)
Total Current Assets
261.58MUSDFY2025 · Dec 31, 2025Total Liabilities
104.17MUSDFY2025 · Dec 31, 2025Total Non-current Assets
28.88MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
78.41MUSDFY2025 · Dec 31, 2025Total Current Liabilities
25.76MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
217.05MUSDFY2025 · Dec 31, 2025Other Short-term Investments
35.95MUSDFY2025 · Dec 31, 2025Accounts Receivable
573.00KUSDFY2025 · Dec 31, 2025Inventory
4.48MUSDFY2025 · Dec 31, 2025Accounts Payable
5.70MUSDFY2025 · Dec 31, 2025Short-term Debt
994.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
464.00KUSDFY2025 · Dec 31, 2025Long-term Debt
76.29MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
525.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
91.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-594.55MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
186.29MUSDvs all stocks (USD)
52-Week Low
1.35USDUpdated Jul 19, 202652-Week High
4.83USDUpdated Jul 19, 202652-Week Change
149.68%vs all stocks
Beta
0.3540xvs all stocks
50-Day MA
4.05USDUpdated Jul 19, 2026200-Day MA
3.83USDUpdated Jul 19, 2026Avg 10-Day Volume
618.98KSharesUpdated Jul 19, 2026Avg 30-Day Volume
906.24KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.07USDUpdated Jul 19, 2026Other Income / Expense
12.03MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 39.97Revenue Growth YoY: -0.91
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 10.18Altman Z-Score: -0.49
Financial Health
Altman Z-Score -0.49: distress zoneCritical
Altman Z-Score: -0.49
Low earnings qualitySignificant
Earnings Quality Score: -0.76
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $9.01M, lower than 95% of all stocks globallySignificant
Revenue (USD): 9,014,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule